Effects of cumulative Herpesviridae and Toxoplasma gondii infections on cognitive function in healthy, bipolar, and schizophrenia subjects

Journal of Clinical Psychiatry

Volumn 78, Issue 1, 2017, Pages e18-e27

  Hamdani, Nora ^a,b,c   Daban Huard, Claire ^a,b,c   Godin, Ophelia ^a,c   Laouamri, Hakim ^c   Jamain, Stéphane ^a,c   Attiba, Dodji ^c   Delavest, Marine ^e   Lépine, Jean Pierre ^e   Le Corvoisier, Philippe ^b   Houenou, Josselin ^a,b,c,d   Richard, Jean Romain ^a,c   Yolken, Robert H ^g   Krishnamoorthy, Rajagopal ^c   Tamouza, Ryad ^c,f   Leboyer, Marion ^a,b,c   Dickerson, Faith B ^h  

^a INSERM U955   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c FONDATION FONDAMENTAL   (France)

^d NeuroSpin   (France)

^e HÔPITAL FERNAND WIDAL   (France)

^f INSERM   (France)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Stanley Research Program   (United States)

Author keywords

Bipolar disorder; Schizophrenia

Indexed keywords

VIRUS ANTIBODY;

ADULT; ARTICLE; BIPOLAR DISORDER; CALIFORNIA VERBAL LEARNING TEST; COMORBIDITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DSM-IV; EPISODIC MEMORY; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NATIONAL ADULT READING TEST; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; VERBAL MEMORY; WECHSLER ADULT INTELLIGENCE SCALE; WORKING MEMORY; COGNITIVE DYSFUNCTION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ENCEPHALITIS, HERPES SIMPLEX; FRANCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; REFERENCE VALUE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TOXOPLASMOSIS, CEREBRAL;

ADULT; BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; COMORBIDITY; CROSS-SECTIONAL STUDIES; ENCEPHALITIS, HERPES SIMPLEX; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REFERENCE VALUES; RISK FACTORS; SCHIZOPHRENIA; TOXOPLASMOSIS, CEREBRAL;

EID: 85012890975     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10133     Document Type: Article

References (67)

1. Bora E. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. Eur Neuropsychopharmacol. 2015;25(2):158-168.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51.
3. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handbook Exp Pharmacol. 2012;213(213):11-37.
4. Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149-162.
5. Hellvin T, Sundet K, Simonsen C, et al. Neurocognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disord. 2012;14(3):227-238.
6. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev. 1995;8(1):131-145.
7. Buka SL, Tsuang MT, Torrey EF, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001;58(11):1032-1037.
8. Dickerson FB, Boronow JJ, Stallings C, et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry. 2003;60(5):466-472.
9. Dickerson FB, Boronow JJ, Stallings C, et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry. 2004;55(6):588-593.
10. Koponen H, Rantakallio P, Veijola J, et al. Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254(1):9-13.
11. Niebuhr DW, Millikan AM, Cowan DN, et al. Selected infectious agents and risk of schizophrenia among US military personnel. Am J Psychiatry. 2008;165(1):99-106.
12. Buka SL, Cannon TD, Torrey EF, et al; Collaborative Study Group on the Perinatal Origins of Severe Psychiatric Disorders. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry. 2008;63(8):809-815.
13. Mortensen PB, Pedersen CB, Hougaard DM, et al. A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res. 2010;122(1-3):257-263.
14. Brown AS. Exposure to prenatal infection and risk of schizophrenia. Front Psychiatry. 2011;2:63.
15. Khandaker GM, Zimbron J, Lewis G, et al. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43(2):239-257.
16. Burkinshaw J, Kirman BH, Sorsby A. Toxoplasmosis in relation to mental deficiency. BMJ. 1953;1(4812):702-704.
17. Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009;31(11):706-715.
18. Kannan G, Pletnikov MV. Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective. Schizophr Bull. 2012;38(6):1155-1161.
19. Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull. 2007;33(3):757-760.
20. Shirts BH, Prasad KM, Pogue-Geile MF, et al. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. Schizophr Res. 2008;106(2-3):268-274.
21. Houenou J, d'Albis MA, Daban C, et al. Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and verbal memory in schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:142-148.
22. Gow AJ, Firth CM, Harrison R, et al. Cytomegalovirus infection and cognitive abilities in old age. Neurobiol Aging. 2013;34(7):1846-1852.
23. Dickerson F, Stallings C, Origoni A, et al. Association between cytomegalovirus antibody levels and cognitive functioning in non-elderly adults. PLoS One. 2014;9(5):e95510.
24. Strandberg TE, Pitkala KH, Linnavuori KH, et al. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke. 2003;34(9):2126-2131.
25. Aiello AE, Haan M, Blythe L, et al. The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc. 2006;54(7):1046-1054.
26. Dickerson F, Stallings C, Sullens A, et al. Association between cognitive functioning, exposure to Herpes Simplex Virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav Immun. 2008;22(7):1103-1107.
27. Gerber SI, Krienke UJ, Biedermann NC, et al. Impaired functioning in euthymic patients with bipolar disorder-HSV-1 as a predictor. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):110-116.
28. Dickerson FB, Boronow JJ, Stallings C, et al. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. Bipolar Disord. 2006;8(2):124-132.
29. Schretlen DJ, Vannorsdall TD, Winicki JM, et al. Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophr Res. 2010;118(1-3):224-231.
30. Yolken RH, Torrey EF, Lieberman JA, et al. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res. 2011;128(1-3):61-65.
31. Dickerson F, Stallings C, Origoni A, et al. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res. 2012;134(1):83-88.
32. Thomas P, Bhatia T, Gauba D, et al. Exposure to herpes simplex virus, type 1 and reduced cognitive function. J Psychiatr Res. 2013;47(11):1680-1685.
33. Prasad KM, Eack SM, Goradia D, et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry. 2011;168(8):822-830.
34. Watson AM, Prasad KM, Klei L, et al. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med. 2013;43(5):1023-1031.
35. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435.
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
37. NIMH Genetics Initiative. Family Interview for Genetic Studies (FIGS). Rockville, MD: National Institute of Mental Health; 1992.
38. Nurnberger JI Jr, Blehar MC, Kaufmann CA, et al; NIMH Genetics Initiative. Diagnostic interview for genetic studies: rationale, unique features, and training. Arch Gen Psychiatry. 1994;51(11):849-859, discussion 863-864.
39. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry suppl. 1993;(22):39-44.
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
41. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
42. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: Adult Version. San Antonio, TX: The Psychological Corporation; 1987.
43. Wechsler D. WAIS-III: Manual for the Wechsler Adults Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
44. Wechsler D. WAIS-III: Manuel de l'Echelle d'Intelligence de Wechsler pour Adultes. 3eme Edition. Additif. Paris, France: Les Editions du Centre de Psychologie Appliquee; 2000.
45. Nelson H. The National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual. Windsor, UK: N-FER-Nelson; 1982.
46. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilit a. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze. 1936;8,3-62.
47. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
48. Stata Statistical Software: Release 13 [computer program]. College Station, TX: StataCorp LP; 2013.
49. Daheshia M, Kanangat S, Rouse BT. Production of key molecules by ocular neutrophils early after herpetic infection of the cornea. Exp Eye Res. 1998;67(6):619-624.
50. Prasad KM, Shirts BH, Yolken RH, et al. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol Psychiatry. 2007;12(1):105-113, 1.
51. Jonker I, Klein HC, Duivis HE, et al. Association between exposure to HSV1 and cognitive functioning in a general population of adolescents: the TRAILS study. PLoS One. 2014;9(7):e101549.
52. Doorduin J. Inhibition of HSV-1 Induced Behavioral Changes and Microglia Cell Activation by Antipsychotics [thesis, chapter 7]. Groningen, The Netherlands: University of Groningen; 2010.
53. Lieb J. Immunopotentiation and inhibition of herpes virus activation during therapy with lithium carbonate. Med Hypotheses. 1981;7(7):885-890.
54. Amsterdam JD, Maislin G, Rybakowski J. A possible antiviral action of lithium carbonate in herpes simplex virus infections. Biol Psychiatry. 1990;27(4):447-453.
55. Boufidou F, Nikolaou C, Alevizos B, et al. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309-313.
56. Hamdani N, Tamouza R, Leboyer M. Immuno-inflammatory markers of bipolar disorder: a review of evidence. Front Biosci (Elite Ed). 2012;4:2170-2182.
57. Libikova H, Pogady J, Wiedermann V, et al. Search for herpetic antibodies in the cerebrospinal fluid in senile dementia and mental retardation. Acta Virol. 1975;19(6):493-495.
58. Baringer JR, Pisani P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann Neurol. 1994;36(6):823-829.
59. Urfer Parnas A, Jansson L, Handest P, et al. Premorbid IQ varies across different definitions of schizophrenia. World Psychiatry. 2007;6(1):38-41.
60. de Miranda AS, Brant F, Campos AC, et al. Evidence for the contribution of adult neurogenesis and hippocampal cell death in experimental cerebral malaria cognitive outcome. Neuroscience. 2015;284:920-933.
61. Leoutsakos JM, Muthen BO, Breitner JC, et al; ADAPT Research Team. Effects of nonsteroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry. 2012;27(4):364-374.
62. Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with agerelated memory loss: randomized controlled study. Am J Geriatr Psychiatry. 2008;16(12):999-1009.
63. Muller N, Riedel M, Schwarz MJ, et al. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):149-151.
64. Prasad KM, Eack SM, Keshavan MS, et al. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-ofconcept randomized double-blind placebo-controlled trial. Schizophr Bull. 2013;39(4):857-866.
65. Malkin JE, Morand P, Malvy D, et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sex Transm Infect. 2002;78(3):201-203.
66. N'Diaye DS, Yazdanpanah Y, Krivine A, et al. Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, France. PLoS One. 2014;9(2):e89857.
67. Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2-3):444-448.